Sector News

Vertex to shutter Canada site in R&D shuffle

March 29, 2017
Life sciences

After posting a disappointing forecast for 2017, Vertex is consolidating its R&D operations, according to a securities filing. The company plans to close a site in Canada, cutting 70 jobs, and trimmed its headcount in Boston, according to a source close to the company.

Vertex “decided to consolidate our research activities into our Boston, Milton Park and San Diego locations,” according to its 10-K. The decision was made last month, the company said, as analysts were chewing over reduced expectations for Vertex’s star cystic fibrosis med, Orkambi.

A spokesperson told FiercePharma the drugmaker chose to close the R&D outfit in Canada “after careful consideration” and offered some employees the chance to relocate. Vertex will expand research efforts at its three remaining hubs, he said.

Meanwhile, at the Boston location, an internal reorganization left 5 to 15 longtime employees without jobs, a source close to the company told FiercePharma. A few employees moved from the Canada office to Boston, the source said, “but most were cut loose.” The cuts in Boston followed a trickle of departures by other veteran staffers.

Vertex’s spokesperson didn’t answer a specific question about cuts in Boston.

About 70 Vertex employees in Canada face losing their jobs. The move will result in restructuring expenses of about $10 million. Radio Canada reported the Laval site is set to close in May.

“Having the right expertise in the right places with the right resources is critical to our mission of bringing more transformative medicines to people with serious diseases,” a Vertex spokesperson wrote. “We are constantly looking for ways to improve the odds of success for our business and for patients.”

Massachusetts’ Labor and Workforce Development office doesn’t have a WARN notice filed from Vertex, according to a spokesperson with that agency. Vertex has about 2,150 employees worldwide, according to its 10-K.

Drugmakers have been focusing their R&D efforts in geographic hubs to save money and, they hope, create collaborative environments where scientists in daily contact build on one another’s ideas. Vertex’s three remaining R&D locations sit in three regions where pharma companies, academic centers and teaching hospitals have created active research networks. Vertex’s Milton Park site is near Oxford, U.K.

The move comes shortly after Vertex trotted out 2017 sales guidance that hit below Wall Street expectations. Facing a hit to Orkambi’s growth, the drugmaker expects between $1.79 billion and $2.01 billion for the year. At the midpoint, it’d be about 17% lower than sell-side expectations, Evercore ISI analyst John Scotti wrote at the time.

Leerink Partners analyst Geoffrey Porges said the company had laid out a “cautious but reasonable” guidance, while Jefferies’ Brian Abrahams figured that the drugmaker could be keeping its Orkambi guidance “in check” as it negotiates for coverage in Europe.

Last fall, Vertex took criticism after execs hinted about a “looming revenue miss” for Orkambi at a fireside chat. That, according to Porges, was “a backhanded slap” to investors—he said the information “warranted a simple 8-K” filing with the SEC, rather than an offhand public reference.

Vertex is predicting between $1.1 billion and $1.3 billion for Orkambi this year.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach